More on FULC

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+17.9% Growth)
- Ratings (2.9 Score)

Upcoming Events

- Earnings (8/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Fulcrum Therapeutics Inc. (NQ:FULC)
Delayed: 3.70 +0.20 (5.71%)
Prev. Close $3.50  
Open$3.56 
52 Wk High$ 
52 Wk Low$ 
Day High$3.71 
Day Low$3.46 
P/E N/A  
EPS$ 
Volume6,101,106 


Jun 11, 2026 04:30 PM Form 8-K Fulcrum Therapeutics, For: Jun 05
Jun 10, 2026 06:13 PM Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: TANG CAPITAL MANAGEMENT LLC
Jun 4, 2026 04:05 PM Form 8-K Fulcrum Therapeutics, For: May 31
Jun 2, 2026 04:26 PM Goldman Sachs Drop Coverage of Fulcrum Therapeutics Inc. (FULC)
Jun 2, 2026 04:26 PM JPMorgan Double Downgrades Fulcrum Therapeutics (FULC) to Underweight
Jun 2, 2026 06:42 AM Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns
Jun 2, 2026 06:07 AM H.C. Wainwright Downgrades Fulcrum Therapeutics (FULC) to Neutral
Jun 2, 2026 06:03 AM Leerink Downgrades Fulcrum Therapeutics (FULC) to Market Perform
Jun 2, 2026 01:08 AM Piper Sandler Double Downgrades Fulcrum Therapeutics (FULC) to Underweight
Jun 2, 2026 01:04 AM Truist Securities Downgrades Fulcrum Therapeutics (FULC) to Hold
View All Articles

Entities mentioned with FULC

View All Entities